STEM CELL THERAPY ON ADVANCED WOUND CARE

The latest and most exciting direction in stem-cell–based wound care in 2026 is shifting from simply putting stem cells into a wound toward regenerative signaling—using mesenchymal stem cells (MSCs), their secretome/exosomes, biomaterials, and combination therapies to rebuild the wound microenvironment.

Where the field stands now

A 2025 systematic review/meta-analysis covering 34 controlled human studies and 2,458 patients found that MSC therapy was associated with significantly faster wound healing and improved new-vessel formation. The authors concluded that MSCs have meaningful therapeutic potential, although the studies and treatment protocols remain heterogeneous. 

The most important developments are:

1. Mesenchymal stem cells (MSCs)
These remain the leading cellular approach. Rather than simply becoming new skin cells, MSCs appear to work largely through paracrine signaling—releasing growth factors and immunomodulatory molecules that influence angiogenesis, inflammation, fibroblasts, keratinocytes and extracellular-matrix remodeling. A 2026 review describes MSC therapy as one of the major emerging approaches for chronic wounds. 

2. MSC-derived exosomes/secretome — arguably the “next generation” ⭐
This is particularly exciting. Instead of transplanting living cells, researchers are investigating the extracellular vesicles/exosomes released by MSCs. They carry proteins, lipids and regulatory RNAs capable of influencing inflammation, angiogenesis and tissue regeneration.

The potential advantages are substantial:

  • easier storage and delivery
  • potentially better safety profile than live-cell transplantation
  • no need for transplanted cells to survive long-term
  • possibility of engineering the exosomes to carry specific therapeutic molecules

The major challenge is still standardization, manufacturing and convincing human clinical evidence.

3. Stem cells + biomaterials/hydrogels
One of the most promising strategies is putting MSCs or their secretome into a 3-D hydrogel/scaffold that stays in contact with the wound and provides sustained release.

Think of it as:

Stem-cell-derived regenerative signals + biologic scaffold + wound bed = localized regenerative environment.

This may ultimately be more effective than simply injecting cells around a chronic ulcer.

4. Combination regenerative therapy
This is where I think advanced wound care is heading.

Instead of:

“Stem cells alone”

the future may be:

Debridement → infection/biofilm control → vascular optimization → off-loading/compression → regenerative biologic → HILT/photobiomodulation → advanced dressing/scaffold → quantitative wound monitoring

The 2025 meta-analysis also found substantial benefit from PRP, supporting the broader concept of using concentrated endogenous regenerative factors rather than relying on one cell type alone. 

The really interesting frontier

I would rank the regenerative technologies roughly like this in terms of scientific excitement vs. clinical maturity. 

A major breakthrough already happening

An important distinction is that cell-based therapy is already becoming a real clinical technology in selected diseases, rather than remaining purely experimental.

For example, in 2025 the FDA approved Zevaskyn (pz-cel), an autologous cell-based gene therapy for recessive dystrophic epidermolysis bullosa, a condition characterized by severe chronic wounds. Patient skin cells are genetically modified and returned as grafts to help restore the defective collagen pathway. 

That’s different from using MSCs for diabetic ulcers, but it demonstrates an important transition: engineered cellular therapies can now reach routine clinical practice in carefully defined wound-related diseases.

Interested on how stem cell therapy can help, see us today  

ZP